OSR (OSRH) and Its Peers Head-To-Head Survey

OSR (NASDAQ:OSRH) is one of 89 publicly-traded companies in the “UNCLASSIFIED” industry, but how does it compare to its peers? We will compare OSR to related companies based on the strength of its risk, profitability, analyst recommendations, dividends, valuation, earnings and institutional ownership.

Valuation & Earnings

This table compares OSR and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	N/A	-$2.41 million	-0.58
OSR Competitors	$40.61 million	-$18.54 million	93.31

OSR’s peers have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

OSR has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -0.08, indicating that their average share price is 108% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for OSR and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	224	265	217	3	2.00

As a group, “UNCLASSIFIED” companies have a potential upside of 85.31%. Given OSR’s peers stronger consensus rating and higher possible upside, analysts plainly believe OSR has less favorable growth aspects than its peers.

Institutional and Insider Ownership

55.3% of OSR shares are held by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are held by institutional investors. 60.6% of OSR shares are held by insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares OSR and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-12.19%	-8.18%
OSR Competitors	0.86%	0.95%	0.80%

Summary

OSR peers beat OSR on 9 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.